SuperworthInmune Bio revenue INMB
Sales by quarter and over the last twelve months, from 2018.
- Last 12 months, to Dec 31, 2025
- $50K
- Latest quarter, Q4 FY25
- $0
- Fiscal year 2025
- $50K
- +257% on the year before
Inmune Bio's revenue was $50K over the twelve months to Dec 31, 2025, up 257% on a year earlier.
In its latest quarter, Q4 FY25, it was $0.
Revenue over time
Fiscal year by fiscal year
| Fiscal year | Revenue | Change |
|---|---|---|
| FY2025 | $50K | +257% |
| FY2024 | $14K | −91% |
| FY2023 | $155K | −59% |
| FY2022 | $374K | +107% |
| FY2021 | $181K | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Revenue | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q4 FY25 | $0 | n/a | $50K | |
| Q3 FY25 | $0 | n/a | $50K | |
| Q2 FY25 | $0 | n/a | $50K | |
| Q1 FY25 | $50K | +257% | $50K | |
| Q4 FY24 | $0 | −100% | $14K | |
| Q3 FY24 | $0 | −100% | $42K | |
| Q2 FY24 | $0 | −100% | $85K | |
| Q1 FY24 | $14K | −63% | $131K | |
| Q4 FY23 | $28K | −71% | $155K | |
| Q3 FY23 | $43K | −56% | $224K | |
| Q2 FY23 | $46K | +188% | $279K | |
| Q1 FY23 | $38K | −77% | $249K |
Against its peers
Companies in Healthcare nearest Inmune Bio's size, closest first, today.
| Company | Revenue, 12 months | Growth |
|---|---|---|
| INMBInmune Bio | n/m | |
| NEPHNephros | $20.7M | +24% a year |
| ATNMActinium Pharmaceuticals | n/m | |
| APTAlpha Pro Tech | $61.9M | +6% a year |
| SPROSpero Therapeutics | $47M | −3% a year |
| LFVNLifevantage | $182.6M | −20% a year |
| ICCCImmucell | $30.7M | +8% a year |
| KEQUKewaunee Scientific | $277.2M | +5% a year |
| PDEXPro DEX | $77.5M | +16% a year |
| PLXProtalix BioTherapeutics | $80.6M | +30% a year |
| NATRNatures Sunshine Products | $492M | +7% a year |
| Peer median | $77.5M |
What the revenue tells you
Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.
Growing revenue with shrinking margins is a warning, not a win.
More on Inmune Bio
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.